Table 3.

Adverse reactions in the two groups

Adverse reaction	Induction therapy stage (n = 118) (%)			Concurrent radiochemotherapy stage (n = 117) (%)
	NPF group (n = 58)	DPF group (n = 60)	P	NPF group (n = 58)	DPF group (n = 59)	P
Leukocytopenia			0.037			0.090
0	20(34.5)	17(28.3)		14(24.1)	11(18.6)
1	28(48.3)	21(35.0)		29(50.0)	24(40.7)
2	7(12.1)	13(21.7)		14(24.1)	20(33.9)
3	3(5.2)	8(13.3)		1(1.7)	4(6.8)
4	0(0)	1(1.7)		0(0)	0(0)
Neutropenia			0.018			0.033
0	19(32.8)	17(28.3)		13(22.4)	9(15.3)
1	27(46.6)	19(31.7)		27(46.6)	20(37.3)
2	9(15.5)	11(18.3)		14(24.1)	22(37.3)
3	3(5.2)	9(15.0)		4(6.9)	6(10.2)
4	0(0)	4(6.7)		0(0)	2(3.4)
Anemia			0.247			0.049
0	49(84.5)	47(78.3)		42(72.4)	33(56.9)
1	9(15.5)	11(18.3)		16(27.6)	23(39.7)
2	0(0)	2(3.3)		0(0)	2(3.4)
Thrombocytopenia			0.452			0.532
0	53(91.4)	53(88.3)		55(94.8)	55(93.2)
1	5(8.6)	6(10.0)		3(5.2)	3(5.1)
2	0(0)	1(0.8)		0(0)	1(1.7)
Liver function damage			0.275			0.178
0	49(84.5)	43(71.7)		46(79.3)	41(69.5)
1	7(12.1)	15(21.6)		12(20.7)	17(28.8)
2	1(1.7)	2(3.3)		0(0)	1(1.7)
3	1(1.7)	0(0)		0(0)	0(0)
Renal function damage			0.166			0.254
0	55(94.8)	53(88.3)		55(94.8)	53(88.3)
1	3(5.2)	6(10.0)		3(5.2)	6(10.0)
2	0(0)	1(1.7)		0(0)	0(0)
Gastrointestinal reaction			0.032			0.037
0	8(13.8)	3(5.0)		9(15.5)	4(6.8)
1	38(65.5)	37(61.7)		32(55.2)	28(47.5)
2	11(19.0)	16(26.7)		16(27.6)	25(42.4)
3	1(1.7)	4(6.7)		1(1.7)	2(3.4)
Oral mucositis			0.099			0.020
0	55(94.8)	51(85.0)		12(20.7)	6(10.2)
1	2(3.4)	6(10.0)		27(46.6)	23(39.0)
2	1(1.7)	3(5.0)		19(32.8)	28(47.5)
3	0(0)	0(0)		0(0)	2(3.4)
skin rash			0.012
0	52(89.7)	60(100)		–	–	–
1	6(10.3)	0(0)		–	–	–
Radiation skin reaction						0.035
0	–	–		8(13.8)	6(10.2)
1	–	–		34(58.6)	25(42.4)
2	–			16(27.6)	26(44.1)
3	–	–		0(0)	2(3.4)